WASHINGTON — The House Ways and Means Committee is poised to vote on a slate of as-yet-unintroduced drug pricing bills that would require sweeping disclosures from both drug middlemen and drug makers, according to summaries of the legislation obtained by STAT.

The committee’s markup, which lobbyists say will be held Tuesday, will follow a flurry of drug pricing action on Capitol Hill in recent days. House Democrats, in particular, appear to be moving toward legislating in earnest on the issue, although which bills will ultimately be signed into law, or the strategy for getting them to the president’s desk, is still unclear.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • The PBM Accountability Act, would require pharmacy middlemen to report their “aggregate rebates, discounts, and other price concessions” to a public website. WOW !!!! Can you Imagine ? Well IT’S ABOUT FU_ _IN TIME!! But , I’ll believe it when I see it !!!
    Yet the PBM’s complained that publicizing their rebates to competitors and drug makers would only make it harder for them to negotiate down the price of drugs. What a set of baseballs they have ! What they meant to say is ” How are we going to steal all those Billions of dollars we’ve
    been doing for so many years ” I guess being transparent makes it harder to negotiate prices. PBM’s must think we’re stupid. Thing are much easier when the PBM’s clients don’t know how much they pay the pharmacies.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy